Improvements in the HIV care continuum needed to meaningfully reduce HIV incidence among men who have sex with men in Baltimore, US: a modelling study for HPTN 078

Kate M Mitchell\textsuperscript{1,3}, Brooke Hoots\textsuperscript{2}, Dobromir Dimitrov\textsuperscript{3}, Danielle German\textsuperscript{4}, Colin Flynn\textsuperscript{5}, Jason E Farley\textsuperscript{6}, Marcy Gelman\textsuperscript{7}, James P Hughes\textsuperscript{3,8}, Deborah Donnell\textsuperscript{3}, Adeola Adeyeye\textsuperscript{9}, Robert H Remien\textsuperscript{10,11}, Chris Beyrer\textsuperscript{12}, Gabriela Paz-Bailey\textsuperscript{13} and Marie-Claude Boily\textsuperscript{1}

\textsuperscript{1}Corresponding author: Kate M Mitchell, Imperial College London, St Mary’s Campus, Norfolk Place, London W2 1PG, UK. Telephone: +44 (0)20 7594 3007. (kate.mitchell@imperial.ac.uk)

Abstract

Introduction: HIV prevalence is high among men who have sex with men (MSM) in Baltimore, Maryland, United States, and the levels of viral suppression among HIV-positive MSM are relatively low. The HIV Prevention Trials Network 078 trial seeks to increase the levels of viral suppression among US MSM by increasing the rates of diagnosis and linkage to care and treatment. We estimated the increases in viral suppression needed to reach different HIV incidence reduction targets, and the impact of meeting diagnosis and treatment targets.

Methods: We used a mathematical model of HIV transmission among MSM from Baltimore, US, parameterised with behavioural data and fitted to HIV prevalence and care continuum data for Baltimore wherever possible, to project increases in viral suppression needed to reduce the HIV incidence rate among Baltimore MSM by 10, 20, 30 or 50\% after 2, 5 and 10 years. We also projected HIV incidence reductions achieved if US national targets – 90\% of people living with HIV (PLHIV) know their HIV serostatus, 90\% of those diagnosed are retained in HIV medical care and 80\% of those diagnosed are virally suppressed – or UNAIDS 90-90-90 targets (90\% of PLHIV know their status, 90\% of those diagnosed receive antiretroviral therapy (ART), 90\% of those receiving ART are virally suppressed) are each met by 2020.

Results: To reduce the HIV incidence rate by 20\% and 50\% after five years (compared with the base-case at the same time point), the proportion of all HIV-positive MSM who are virally suppressed must increase above 2015 levels by a median 13 percentage points (95\% uncertainty interval 9 to 16 percentage points) from median 49\% to 60\%, and 27 percentage points (22 to 35) from 49\% to 75\% respectively. Meeting all three US or 90-90-90 UNAIDS targets results in a 48\% (31\% to 63\%) and 51\% (38\% to 65\%) HIV incidence rate reduction in 2020 respectively.

Conclusions: Substantial improvements in levels of viral suppression will be needed to achieve significant incidence reductions among MSM in Baltimore, and to meet 2020 US and UNAIDS targets. Future modelling studies should additionally consider the impact of pre-exposure prophylaxis for MSM.

Keywords: HIV infections; incidence; homosexuality, male; models, theoretical; United States; forecasting

Additional Supporting Information may be found online in the Supporting information tab for this article.
Targets designed to improve viral suppression levels and reduce HIV incidence by 2020 have been put forward for the US [10], and by UNAIDS [11]. US targets include reducing the total number of new HIV diagnoses in 2020 by at least 25% compared with 2010 (US new diagnoses target), while increasing the percentage of people living with HIV (PLHIV) who know their serostatus to 90%, the percentage of those diagnosed who are in care to 90%, and the percentage of diagnosed persons who are virally suppressed to 80% by 2020 (US continuum targets) [10]. The UNAIDS continuum “90-90-90” targets aim to increase the percentages of PLHIV who know their HIV status, diagnosed PLHIV receiving ART, and PLHIV receiving ART who are virally suppressed each to 90% by 2020 [11]. Note that those receiving ART (UNAIDS target 2) are a subset of those in care (US target 2).

The HIV Prevention Trials Network (HPTN) 078 trial, ongoing since March 2016 among MSM in four US cities including Baltimore, aims to increase diagnosis, linkage to care and ART use for HIV-positive MSM (https://www.hptn.org/research/studies/154). The primary trial objectives are to assess the ability of deep-chain respondent-driven sampling (using long multi-wave recruitment chains) to identify non-virally suppressed HIV-positive MSM, and to test the efficacy of an enhanced case-manager intervention package for helping participants to achieve and sustain viral suppression two years after being assigned to the intervention. The trial protocol includes two modelling objectives. The first objective is addressed in this analysis, prior to obtaining trial results, using the best available data. The second objective will be addressed after trial completion, using the same model with trial data to assess the impact of the study intervention on HIV incidence in the wider MSM population in each of the four cities.

In this analysis, we developed and used a mathematical model of HIV transmission and treatment for US MSM, parameterized for Baltimore, to project (1) the increase in viral suppression needed to reduce the HIV incidence rate among MSM by 10, 20, 30 or 50% after 2, 5 or 10 years (representing reduction targets that may be chosen by health departments or clinical trials [10,12-14]), (2) reduction in HIV incidence achieved if US or UNAIDS targets are met and (3) potential for HIV elimination among MSM in Baltimore.

2 | METHODS

2.1 | Model structure

We developed a deterministic, compartmental dynamic model of HIV transmission and treatment for US MSM, taking into account demography, HIV natural history (disease progression) and interventions (Figures S1,S2,S3).

The model divides the MSM population by age (young: 18 to 24, older: >24 years old [15]), race (black, white), infection status, set-point viral load (SPVL), stage of disease progression by CD4 T-cell count and HIV care continuum stage.

Uninfected MSM join the modelled population through ageing in, sexual debut, or migration, and MSM leave through HIV-related and unrelated mortality, migration or ceasing to attend surveillance venues (such as bars, clubs and cafés).

Following HIV acquisition, modelled individuals move into the high-infectivity acute stage, and then into one of 16 chronic infection states defined by SPVL and CD4 count [16]. Those not on ART, and those on ART but non-adherent, move through progressively lower CD4 states [16]; those adherent to ART do not. Increases in CD4 count for those adherent to ART are not explicitly modelled, but survival on ART is modelled as a function of initial CD4 count.

In the model, any HIV-positive MSM can be diagnosed and start ART once symptomatic. A fraction are assumed to never routinely test for HIV. Other HIV-positive MSM routinely test (at age- and race-specific rates) and leave the undiagnosed state, with a proportion assumed to link directly into care, while the remainder are diagnosed but unlinked, and may subsequently move into care. Those in care may dropout into the diagnosed unlinked state. Those in care may initiate ART, with changes over time in ART eligibility (related to CD4 count) explicitly modelled following past CDC guidelines (Table S1). A proportion are adherent, achieving full viral suppression following a short period of partial suppression; the non-adherent remainder do not achieve viral suppression (loss and regain of viral suppression are not explicitly modelled, due to a lack of data). Those on ART can drop out of care, and may subsequently re-initiate ART following care re-engagement.

Modelling HIV transmission occurs in main, casual and commercial sexual partnerships with men, which differ in number of sex acts and condom use. The age- and race-specific per-capita infection rate depends upon numbers of new partners/year, sex acts/partnership, transmission probability/sex act, circumcision status, condom use, and HIV prevalence, viral load, infection stage and viral suppression among sexual partners.

The model was expressed as a set of differential equations, solved numerically in C++ using a variable-stepsize eighth-order Runge-Kutta method [17]. See Supporting Information for equations and further details.

2.2 | Model calibration

The model was parameterized using data from multiple sources (see section 2.2.1), and fitted to Baltimore MSM data in four steps: (1) we defined plausible ranges of values for all parameters in five domains: demography, sexual behaviour, HIV natural history and infectivity, care continuum and intervention efficacies, (2) sampled all parameter ranges one million times using Latin Hypercube sampling [18] and, with each parameter set, simulated the HIV epidemic from 1984 until 2016, (3) retained parameter sets for which model predictions simultaneously agreed with demographic, epidemiological and care continuum fitting outcome estimates before 2014 (Tables 1 and S2), (4) compared model predictions for these retained parameter sets with 2014 to 2017 demographic, epidemiological and care continuum validation data.

2.2.1 | Data sources – model parameters and fitting outcomes

Local data sources informed demography, sexual behaviour and care continuum parameters wherever possible [3,5,19-21]. HIV natural history, infectivity and intervention efficacy parameters were drawn from published literature, on MSM and/or Western populations where possible.

NHBS were serial cross-sectional studies conducted among MSM in Baltimore [3,19,20]. Data collection methods have been described previously [22]. Briefly, MSM aged over 18
were recruited using venue-based, time-space sampling, administered a face-to-face behavioural interview and HIV testing. NHBS data collection was approved by the Maryland Department of Health (DH), Johns Hopkins Bloomberg School of Public Health Institutional Review Boards, and CDC. All those with a valid HIV test result reporting sex with another man in the last 12 months were included in the current analysis. Individual-level data were analysed using SAS 9.4 (SAS Institute, Cary, NC, USA). Clusters (at the recruitment venue level) were taken into account using the SAS surveymeans and surveyfreq procedures.

Data for MSM from the Johns Hopkins HIV cohort [21] and data from NA-ACCORD from Fenway electronic monitoring data were used to estimate median time to viral suppression stratified by initial viral load.

Estimates and sources for key behaviour and care continuum parameters are presented in Table 1, and for all parameters in Table S1. See Supporting Information for further details.

Demographic, epidemiological and care continuum fitting (pre-2014) or validation (2014 to 2017) outcomes were based on local data sources, plus national estimates for levels of viral suppression among those on ART [23,24]. Data informing ART coverage came from a Baltimore MSM NHBS sub-study (2008 to 2014), which tested stored sera for antiretrovirals [25] among participants who consented to storage for future testing. Fitting outcomes and sources are summarized in Table 1, full details in Table S2.

2.3 | Plan of analysis

2.3.1 | Addressing uncertainties across data sources

Different data sources provided incompatible estimates — that is if the model was fitted to one data source, it did not fit the other — for three fitting outcomes. To address this uncertainty, we defined six fitting assumptions, using different ranges for relevant input parameters (Table S1) in order to fit to different data sources (Table S2). We fitted to two age/race distribution assumptions, from either (1) NHBS or (2) census data. We used two diagnosis assumptions, either (3) using NHBS testing rate parameters or (4) fitting the percentage of diagnosed MSM to Maryland CDC estimates. We defined two care continuum assumptions, fitting to (5) NHBS ART or (6) DH continuum data (further details in Supporting Information). Using all combinations of these fitting assumptions gave eight groups of model fits.

2.3.2 | Base-case scenario

Each retained parameter set was used to project the HIV epidemic from 1984 to 2036 (to allow examination of elimination over a 20 year period after 2016), in a base-case scenario assuming rates of HIV testing, linkage to care, ART initiation, adherence and dropout remain at 2015 levels until 2036.

2.3.3 | Intervention scenarios

To project (1) required increases in viral suppression to reach incidence reduction targets and (2) HIV incidence reductions if US and UNAIDS targets are met, we explored different improved care continuum parameters, introduced in 2016 (as an instantaneous step change). We used Latin Hypercube sampling to select 1600 combinations of improved continuum parameter values sampled between 2015 levels and most optimistic values (in brackets): percentage HIV tested (98% tested/year), percentage of tested linked (100% link directly into care after diagnosis), rate of linkage into care (4/year/person among those diagnosed but unlinked (i.e. after average three months)), ART initiation rate (6/year/person (after average two months)), percentage ART adherent (100%), ART dropout rate (0%). All parameters were improved simultaneously in 2016 and maintained until 2036. We re-ran each of the retained fitting parameter sets (from model calibration step 3) with each of these 1600 improved continuum parameter combinations in turn, and identified all combinations where the (1) HIV incidence rate reduction or (2) percentage at different care stages, fell within ±0.5 percentage points of pre-defined targets (below). We used these to answer five questions.

2.3.4 | Question 1: What increase in viral suppression is needed to reach predefined HIV incidence reduction targets?

The targets were as follows: 10, 20, 30 or 50% relative reduction in HIV incidence rate 2, 5 or 10 years after care continuum parameters were improved at the start of 2016, compared with base-case scenario at the same time-points. Incidence is measured over a one-year period.

For each intervention scenario meeting each target, we projected the absolute increase above 2015 levels in the percentage of HIV-positive men virally suppressed at the time the target was met (Figure S4a,b). In the main analysis, results are pooled across the eight groups of model fits, to account for all of the uncertainty arising from different data sources. Results are also stratified by fitting assumption, to assess the sensitivity of results to these assumptions.

2.3.5 | Question 2: What care continuum improvements are needed to meet HIV incidence reduction targets?

We projected the expected levels of different care continuum indicators (diagnosed/in care/on ART/virally suppressed) when meeting incidence reduction targets after 2, 5 and 10 years, pooling results across the eight groups of model fits. We calculated Pearson correlation coefficients between the increase in each care continuum parameter above 2015 levels and HIV incidence rate reductions after five years across all intervention scenarios.

2.3.6 | Question 3: What reduction in HIV incidence will be achieved if US and UNAIDS targets are met in 2020?

1. US new diagnoses target: relative decline in new HIV diagnoses of 25% from 2010 to 2020.
2. US continuum targets: 90% of HIV-positive diagnosed, 90% of diagnosed in care, 80% of diagnosed virally suppressed.
3. UNAIDS continuum targets: 90% of HIV-positive diagnosed, 90% of diagnosed on treatment, 90% of treated virally suppressed.

We projected the relative reduction in HIV incidence rate compared with the base-case scenario in 2020, across intervention scenarios meeting US and UNAIDS targets (Figure S4c,d).
### Table 1. Summary of key sexual behaviour, care continuum and intervention efficacy parameters and fitting outcomes

| Parameters | Range | Source |
|------------|-------|--------|
| **Sexual behaviour parameters** |       |        |
| Average number of new main anal sex partners per year 2011<sup>a</sup> |       |        |
| 18- to 24-year-old black MSM | 0.58 to 0.8<sup>b</sup> | Baltimore NHBS |
| >24-year-old black MSM | 0.36 to 0.57<sup>b</sup> |       |
| 18- to 24-year-old white MSM | 0.08 to 0.37<sup>b</sup> |       |
| >24-year-old white MSM | 0.11 to 0.21<sup>b</sup> |       |
| Average number of new casual anal sex partners per year 2011<sup>a</sup> |       |        |
| 18- to 24-year-old black MSM | 1.54 to 2.09<sup>b</sup> | Baltimore NHBS |
| >24-year-old black MSM | 0.81 to 1.24<sup>b</sup> |       |
| 18- to 24-year-old white MSM | 0.05 to 0.93<sup>b</sup> |       |
| >24-year-old white MSM | 0.28 to 1.07<sup>b</sup> |       |
| Average number of new commercial anal sex partners per year 2011<sup>a</sup> |       |        |
| 18- to 24-year-old black MSM | 0 to 1.36<sup>b</sup> | Baltimore NHBS |
| >24-year-old black MSM | 0.15 to 0.85<sup>b</sup> |       |
| 18- to 24-year-old white MSM | 0 to 0.28<sup>b</sup> |       |
| >24-year-old white MSM | 0 to 0.07<sup>b</sup> |       |
| Percentage of sex acts in which condom used 2011<sup>a</sup> |       |        |
| Main partnerships, both partners black | 47 to 67 | Baltimore NHBS |
| Main partnerships, either partner white | 30 to 39 |       |
| Casual partnerships (any race partner) | 63 to 72 |       |
| Commercial partnerships (any race partner) | 21 to 78 |       |
| **Care continuum parameters** |       |        |
| Percentage of undiagnosed MSM testing for HIV per year, 2011<sup>a</sup> |       |        |
| 18- to 24-year-old black MSM | 63.8 to 95.0 | Baltimore NHBS |
| >24-year-old black MSM | 50.0 to 70.2 |       |
| 18- to 24-year-old white MSM | 32.1 to 82.3 |       |
| >24-year-old white MSM | 32.7 to 69.7 |       |
| Percentage of white MSM testing positive for HIV who are immediately linked to care, 2008<sup>a</sup> | 67 to 85 | Maryland DH Baltimore data, national US MSM estimates (data on linkage within three months of diagnosis) [24,35] |
| Ratio of percentage of black MSM linking to care immediately compared to white MSM | 0.84 to 1.5 |       |
| Rate of linkage to care per year for those not linking immediately or dropped out, white MSM, 2008<sup>a</sup> | 0 to 0.5 | Fitted |
| Ratio of rate of linkage to care for black MSM compared to white MSM | 0.84 to 2 | National US MSM estimates [24,35] |
| Rate of initiation onto ART from care per year, when meeting CD4 criteria, all years; permitted to differ by race | 0.5 to 4 | CD4 testing every 3 to 6 months (national guidelines), 80 to 90% acceptance [36] |
| Percentage of white MSM initiating ART who are adherent (achieve viral suppression), all years | 73 to 99 | US studies (multiple sites) [24,37–39] |
| Ratio of percentage adherent to ART black: white MSM | 0.82 to 1 | US studies (multiple sites) [24,37–39] |
| Rate of dropout from ART per year first two years on ART, all years | 0.06 to 0.13 | US studies (multiple sites) [40–43] |
| Ratio of dropout from ART third+ years on ART; first two years on ART | 0.5 to 1.0 | US ART cohorts (multiple sites) [44] |
| Ratio of rate of dropout from care: rate of dropout from ART, black MSM | 1 to 7 | US studies (multiple sites) [41,42,45,46] |
| Ratio of dropout from care for white: black MSM | 0.46 to 3 | US studies (multiple sites) [41,42,45] |
| **Intervention efficacies** |       |        |
| Per-sex-act reduction in HIV acquisition risk due to correct condom use (%) | 58 to 79 | US MSM estimates (multiple sites) [47] |
| Per-sex-act reduction in HIV acquisition risk due to male circumcision (%) | 12 to 23 | Assuming efficacy only for insertive anal sex |
| Per-sex-act reduction in HIV transmission risk due to being on ART and fully suppressed (%) | 99 to 100 | European MSM estimates (multiple countries) [8] |
2.3.7 | Question 4: What reduction in HIV incidence will be seen if the HPTN 078 trial target effect size is achieved?

The HPTN 078 trial was powered to detect an 18 percentage point difference in levels of viral suppression between men receiving a case-manager intervention or standard of care, two years after enrolment. We projected the relative reduction in HIV incidence rate compared with the base-case scenario when the percentage of diagnosed MSM virally suppressed is 18 percentage points higher in the intervention than the base-case scenario after two years.

2.3.8 | Question 5: What is the potential for local HIV elimination?

We recorded how often HIV elimination (defined as HIV incidence <1 infection/1000 person-years [26]) occurred before 2036 in base-case and intervention scenarios meeting incidence reduction, US, or UNAIDS targets.

3 | RESULTS

3.1 | Model fits

Altogether, 169 unique parameter combinations, pooled across the eight groups of model fits, fitted available data. The model fitted age- and race-specific HIV prevalence well, and adequately predicted 2014 HIV prevalence validation data, but slightly overestimated prevalence among older white MSM (Figure 1a,b,c,d).

Fits to NHBS ART coverage data gave higher estimates of percentages in care, on ART and virally suppressed (median 2015 estimates: 76%, 69% and 59% respectively), than fits to DH continuum data (median 2015 estimates: 63%, 49% and 41% respectively) (Figure S5f,g,h,i,j,k,l). The model predicted 2014 NHBS age/race and ART coverage and 2014 to 2017 DH care validation data well under the corresponding assumptions, but tended to underestimate 2014 to 2017 DH viral suppression (Figure S5a,b,c,d, f,g,h,j,k,l).
Viral suppression levels were projected to increase over time, reaching 49% (95% uncertainty interval (UI) 29% to 58%) of HIV-positive MSM at the end of 2015 (Figure 1e).

### 3.2 | Base-case scenario

Under the base-case scenario (keeping continuum parameters at 2015 levels), viral suppression levels continue to increase after 2015, by a median 2, 3 and 4 percentage points above 2015 levels after 2, 5 and 10 years respectively. Under the base-case scenario, projected annual HIV incidence declines from 3.3 (UI 1.8 to 5.0)/100 py in 2015 to 3.0/100 py in 2017, 2.7/100 py in 2020 and 2.4/100 py in 2025.

### 3.3 | Analysis

#### 3.3.1 | Question 1: What increase in viral suppression is needed to reach predefined HIV incidence reduction targets?

The annual HIV incidence rate is projected to be reduced by 20% (compared to the base-case scenario at the same time point) after 2, 5 and 10 years if viral suppression levels are increased by 13 (UI 11 to 18), 13 (9 to 6) and 12 (8 to 17) percentage points above 2015 levels (increasing from 49% in 2015 to 61%, 60%, and 60%) after 2, 5 and 10 years respectively (Figure 2a; note that the median increase does not always exactly match the difference between the median initial and final levels). Higher suppression levels are needed to achieve a 50% incidence rate reduction (compared to the base-case scenario) after 2, 5 and 10 years: viral suppression must be increased by 30 (24 to 39), 27 (22 to 35) and 25 (20 to 32) percentage points above 2015 levels respectively (Figure 2a).

The increase in viral suppression needed to reach a 50% incidence rate reduction target after five years is similar across the different demography and diagnosis fitting assumptions (Figure 2b). However, smaller increases in viral suppression are needed under the NHLBS ART coverage data fitting assumption than under the DH continuum data assumption. Smaller increases in viral suppression are required to produce the same incidence reduction for higher 2015 viral suppression levels (Figure S6). Subsequent results are pooled across the eight groups of model fits.

#### 3.3.2 | Question 2: What care continuum improvements are needed to meet HIV incidence reduction targets?

Due to high 2015 levels of diagnosis and viral suppression amongst those treated, only small improvements in these indicators can be achieved, and so only small increases in these indicators were necessary (along with increases in other indicators) for incidence reduction targets to be met (Figure 3a, d). More substantial increases in care and ART indicators were needed to meet the most ambitious target of 50% incidence reduction – while improving all continuum parameters simultaneously, to meet this target after five years the percentage of diagnosed in care reaches 89%, and diagnosed on ART 86%, from 72% and 66% in 2015 (Figure 3b,c).

#### 3.3.3 | Question 3: What reduction in HIV incidence will be achieved if US and UNAIDS targets are met in 2020?

For 43% of fits, the model projects the US new diagnoses target (25% relative decline in new HIV diagnoses between 2010 and 2020) will be met in the base-case scenario, without continuum parameter improvements, since HIV incidence – and diagnoses – are already declining in the base-case, and this target uses a historical comparator. On average, this target could be met if viral suppression in 2020 increased by 6 (UI 1 to 23) percentage points above 2015 levels, only producing a 5% (0% to 32%) relative HIV incidence rate reduction compared with the base-case scenario in 2020 (Figure S8). This small reduction in incidence occurs because the comparator is the base-case scenario, in which incidence is also declining, rather than a historical comparator.

Achieving the 90% diagnosis target in 2020 (while improving all care continuum parameters simultaneously) has a limited impact, reducing the HIV incidence rate (compared with base-case in 2020) by 18% (Figure 4a). However, greater reductions in HIV incidence rates (48% to 50%) are achieved in 2020 by either attaining the US continuum indicator targets of 90% diagnosed in care, 80% of diagnosed virally suppressed, or all three continuum targets simultaneously, giving 72% to 75% of MSM virally suppressed in 2020 (Figure 4a,b). Meeting the three UNAIDS continuum targets together results in similar HIV incidence reduction (51%) and viral suppression level (76%) as meeting US continuum targets (48% incidence reduction, 75% virally suppressed; Figure 4c,d).

#### 3.3.4 | Question 4: What reduction in HIV incidence will be seen if the HPTN 078 trial target effect size is achieved?

If the percentage of diagnosed MSM virally suppressed is 18 percentage points higher in the intervention than the base-case scenario after two years, the model projects a 35% (UI 21% to 43%) reduction in HIV incidence versus base-case (data not shown).
3.3.5 | Question 5: What is the potential for local HIV elimination?

HIV elimination (incidence <1/1000 person-years) is never achieved before 2036 in base-case scenarios, and is unlikely to be achieved by 2036 under any of the incidence reduction, US, or UNAIDS targets investigated, occurring in at most 6% of model runs (Figure S9, Table S3).

4 | DISCUSSION

Our model results provide important insights for HIV prevention in Baltimore and the US. First, our results suggest HIV incidence is already declining among Baltimore MSM under current rates of HIV testing, linkage, and ART initiation. This means the US new diagnoses target (25% relative decline in new HIV diagnoses between 2010 and 2020) could be met with minor continuum improvements, but this is expected to only produce a small (5%) reduction in HIV incidence rate in 2020 compared with base-case scenarios where current HIV testing, linkage, and ART initiation rates are maintained. Second, large increases in viral suppression – associated with large ART coverage increases – are needed to significantly reduce HIV incidence rates among MSM in Baltimore compared with base-case scenario projections. To reduce HIV incidence rates by 50% compared to base-case after five years, viral suppression levels must increase by 27 percentage points above 2015 levels, and 13 percentage points to reduce incidence by 20%. Third, the small HIV incidence reduction projected when meeting the US new diagnoses target contrasts with the 48% reduction in HIV incidence rate expected from meeting US continuum targets, highlighting poor alignment between the new diagnoses and continuum targets. Fourth, local elimination of HIV (incidence below 0.1%/year) among Baltimore MSM is unlikely to occur in the next 20 years, even if US or UNAIDS targets are reached.
suggesting additional primary prevention efforts (e.g. pre-exposure prophylaxis (PrEP) or a vaccine) are needed to achieve elimination. Fifth, our results emphasize the importance of achieving low rates of ART dropout, and high ART initiation rates and adherence levels to achieve substantial HIV incidence reductions.

4.1 | Limitations

Where possible, we used data from Baltimore. However, some behavioural parameters were sourced from other US locations. Therefore, we may not have fully captured local care continuum progression. Our model did not fully capture the
decline in prevalence among older white MSM in the 2014 NHBS. This lower prevalence could partly have resulted from different venues being sampled in the 2014 NHBS than at earlier surveys. Overestimating HIV prevalence among white MSM could mean we underestimated base-case scenario HIV incidence declines, although since our model captured
prevalence trends among black MSM – who account for most HIV-positive MSM in Baltimore – very well, this is unlikely to greatly impact our results. Due to limited data, we excluded MSM of Hispanic ethnicity, who are a small proportion (<5%) of MSM in Baltimore but have low viral suppression (43% in 2015 [5]), due to low levels of engagement in care and suboptimal suppression among those in care. New diagnoses among Hispanic MSM in Maryland have declined in recent years proportionately to overall MSM diagnoses [27], suggesting no significant local incidence differences among Hispanic MSM which might affect our results. NHBS data are collected only from MSM recruited from MSM-identified venues, and may not reflect the demographic, behavioural and HIV-related characteristics of the broader Baltimore MSM population (although we showed that our results were not sensitive to NHBS demography and HIV testing data – Figure 2b). In fits to DH continuum data, our model underestimated levels of viral suppression over the period 2014 to 2017; however, as we also fitted the model to ART coverage data, our results cover situations where viral suppression is similar to DH 2014 to 2017 estimates. In intervention scenarios we assumed instantaneous care continuum parameter improvements, therefore our estimates likely overestimate achievable impact, particularly in the short-term (1 to 2 years). Transmission via injection drug use was not included in our model. In DH surveillance, only 14% of diagnosed PLHIV with MSM exposure also have injecting drug use exposure [5], suggesting little overlap between the MSM and injection drug use epidemics.

Few studies have assessed the potential impact upon HIV incidence of meeting UNAIDS 90-90-90 targets in the US. Risk equation modelling projected that if the US reached the UNAIDS 90-90-90 targets by 2020 at the national level, HIV incidence could be reduced by 50% [28], aligning closely with our 51% incidence reduction projection for meeting UNAIDS targets among Baltimore MSM. Another modelling study projected a slightly smaller 40% reduction in HIV incidence [29]. A recent modelling study suggested that meeting the US target to have 90% of diagnosed PLHIV in care by 2020 would reduce US national HIV incidence (vs. base-case) by around 56% [30], higher than our projected 48% reduction – this is likely due to lower baseline levels of PLHIV in care in their study. In agreement with our findings, they found a much smaller impact of reaching the 90% diagnosed target [30]. Another modelling study suggested slightly more modest national impact (46% incidence decline from 2013 to 2020) when US 2020 targets are met [31].

Baltimore is currently expanding access to PrEP for HIV at-risk and uninfected adults, including MSM. PrEP was not included in this analysis as reported use in the 2014 Baltimore MSM NHBS was very low, and more recent city-level coverage data are not yet available. State-level estimates of PrEP usage [27] suggest around 2% of uninfected MSM in Maryland are using PrEP. This level of use would minimally affect our results; however, substantial scale-up of PrEP in the near future would mean that smaller increases in viral suppression would be needed to meet HIV incidence reduction targets. Data from other communities with high MSM HIV burdens suggest that improvements in the care continuum for HIV-positive MSM and significant levels of PrEP uptake can have synergistic impacts on HIV incidence [32,33].

Our analysis has highlighted incompatibilities between different data sources, including current levels of viral suppression among MSM in Baltimore. Estimates of ART coverage obtained from antiretroviral detection in plasma in the Baltimore MSM NHBS sub-study suggest higher levels of viral suppression (59% for model fits, 2015) than DH estimates of viral suppression among diagnosed MSM (data estimate 46%, 2015). As NHBS participants may not be representative of the wider MSM population the sub-study could have overestimated true ART coverage. DH statistics may underestimate viral suppression levels, as viral load measurements were only available for 54% of diagnosed Baltimore MSM in 2015. Our results fully account for the resulting uncertainty, with uncertainty ranges including pessimistic and optimistic values, but as this uncertainty influenced our results, these differences warrant further investigation.

The model projects that if the HPTN 078 trial achieves its target effect size – an 18 percentage point difference in viral suppression levels between trial arms after two years – this would achieve a 35% reduction in incidence compared with the base-case scenario. Greater differences – approximately 30 percentage points – are needed to achieve 50% incidence reduction.

Future modelling studies should assess the efforts needed and resulting impact of meeting these targets in other US settings. They should also consider in what ways prioritizing and investing in interventions to groups most affected by HIV transmission could increase efficiency in these settings, and whether advances in primary prevention, including oral PrEP, can further accelerate incidence declines and achieve elimination.

5 | CONCLUSIONS

Our model suggests HIV incidence is already declining among MSM in Baltimore, but to achieve more rapid HIV incidence reductions, more intense efforts are needed to strengthen multiple points along the care continuum, particularly improving linkage to care, ART retention and long-term adherence. This will require substantial investment and attention to the multi-layered social and structural influences affecting Baltimore MSM, especially black MSM [34]. Meeting US and UNAIDS targets is likely to reduce HIV incidence rates by around 50% in 2020, but will require large increases in ART coverage, and additional primary prevention efforts will be needed to achieve HIV elimination in the near future.

AUTHORS’ AFFILIATIONS

1Department of Infectious Disease Epidemiology, Imperial College London, HPTN Modelling Centre, London, UK; 2Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA; 3Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 4Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; 5Center for HIV Surveillance, Epidemiology and Evaluation, Maryland Department of Health, Baltimore, MD, USA; 6Department of Community-Public Health, Johns Hopkins University School of Nursing, Baltimore, MD, USA; 7The Fenway Institute, Fenway Health, Boston, MA, USA; 8Department of Biostatistics, University of Washington, Seattle, WA, USA; 9Division of AIDS, NIAID, National Institutes of Health, Washington, DC, USA; 10HIV Center for Clinical and Behavioral Studies, NY State Psychiatric
COMPETING INTERESTS

The authors declare that they have no competing interests.

AUTHORS’ CONTRIBUTIONS

Marie-Claude Boily, Dobromir Dimitrov, Kate M Mitchell, Gabriela Paz-Bailey, Danielle German, Colin Flynn, James P. Hughes, Deborah Donnell, Adeola Adeyeye, Robert H Remien and Chris Beyrer contributed to study conceptualization. Brooke Hoots and Gabriela Paz-Bailey curated the NHBS data. Kate M Mitchell conducted the modelling and Brooke Hoots conducted the main NHBS data analysis. Marie-Claude Boily, Deborah Donnell, Chris Beyrer and Robert H Remien acquired funding. Kate M Mitchell, Danielle German, Colin Flynn, Jason E. Farley, Marcy Gelman, Gabriela Paz-Bailey contributed to other data analyses. Kate M Mitchell, Marie-Claude Boily and Dobromir Dimitrov designed the modelling methodology. Kate M Mitchell developed the model code. Marie-Claude Boily oversaw the study. Kate M Mitchell and Marie-Claude Boily wrote the initial draft of the manuscript. Kate M Mitchell, Brooke Hoots, Dobromir Dimitrov, Danielle German, Colin Flynn, Jason E. Farley, Marcy Gelman, James P. Hughes, Deborah Donnell, Adeola Adeyeye, Robert H Remien, Chris Beyrer, Gabriela Paz-Bailey and Marie-Claude Boily reviewed and edited the manuscript. All authors have read and approved the final manuscript.

ACKNOWLEDGEMENTS

We thank Kate Shearer for her assistance with the NHBS ARV data. KMM, MCB and D Dimitrov are supported by the HPTN Modelling Centre which is funded by the US National Institutes of Health (www.nih.gov/; grant number UM1AI066817) through the HPTN Statistical and Data Management Center. The HPTN 071 (UMC, PPR CB) is funded by the National Institute of Allergy and Infectious Diseases (www.niaid.nih.gov), with co-funding from the National Institute of Mental Health (www.nimh.nih.gov), and the National Institute on Drug Abuse (www.drugabuse.gov), all components of the US National Institutes of Health (www.nih.gov). The work presented here was funded under the NIH cooperative agreements UM1AI066817 and UM1AI066819. Baltimore NHBS is supported through contracts to The Johns Hopkins University from the Maryland Department of Health and by cooperative agreements between the Maryland Department of Health and the Centers for Disease Control and Prevention, and the infrastructure, resources, and services of the Johns Hopkins University Center for AIDS Research, an NIH funded program (P30AI094189). DG is additionally supported by the National Institutes of Health (K01DA041259). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

DISCLAIMER

The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

REFERENCES

1. Ackers ML, Greenberg AE, Lin CY, Bartholow BN, Goodman AH, Longhi M, et al. High and persistent HIV seroincidence in men who have sex with men across 47 U.S. cities. PLoS ONE. 2012;7(4):e39972.
2. Preleunig J, Song R, Hernandez A, Zielbèl R, Green T, Walker F, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS ONE. 2011;6(8):e17502.
3. Wejnert C, Le B, Rose CE, Oster AM, Smith AJ, Zhu J, et al. HIV infection and awareness among men who have sex with men across 20 U.S. cities. PLoS ONE. 2012;7(4):e39972.
4. Hall HI, An Q, Tang T, Song R, Chen M, Green T, et al. Prevalence of diagnosed and undiagnosed HIV infection – United States, 2008-2012. MMWR Morb Mortal Wkly Rep. 2015;64(24):657–62.
5. Center for HIV Surveillance Epidemiology and Evaluation Maryland Department of Health and Mental Hygiene. Baltimore City annual HIV epidemiological profile 2015. Baltimore (MD): Center for HIV Surveillance Epidemiology and Evaluation Maryland Department of Health and Mental Hygiene; 2016.
6. Antiretroviral Therapy Cohort Collaboration. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients. J Acquir Immune Defic Syndr. 2007;46(5):607–15.
7. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumaranayake N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(4):493–505.
8. Rodríguez AJ, Cambiano V, Braun T, Vernazza P, Collins S, van Lunzen J, et al. Sexual activity without condom and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316(2):171–81.
9. Tanser F, Barnighausen T, Graepa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339(6122):966–71.
10. White House Office of National AIDS Policy. National HIV/AIDS strategy for the United States: updated to 2020. Washington (DC): White House Office of National AIDS Policy; 2015.
11. UNAIDS. 90–90–90 An ambitious treatment target to help end the AIDS epidemic. Geneva: UNAIDS; 2014.
12. Choopanya K, Martin M, Suntaraksamai P, Sangkum U, Mock PA, Leethachawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovird Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.
13. Van Damme L, Corneli A, Ahmed K, Agot K, Lombard J, Kajiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411–22.
14. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Preexposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.
15. Sullivan PS, Rosenberg ES, Sanchez TH, Kelley CF, Luisi N, Cooper HL, et al. Explaining racial disparities in HIV incidence in black and white men who have sex with men in Atlanta, GA: a prospective observational cohort study. Ann Epidemiol. 2015;25(6):445–54.
16. Cori A, Pickles M, van Sighem A, Gras L, Bezemer D, Reiss P, et al. CD4+ cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, sex and calendar time. AIDS. 2015;29(18):2435–46.
17. Press WH, Teukolsky SA, Vetterling WT, Flannery BP. Numerical recipes: the art of scientific computing. 3rd ed. New York: Cambridge University Press; 2007.
18. Blower SM, Dowlatabadi H. Sensitivity and uncertainty analysis of complex models of disease transmission – an HIV model, as an example. Int Stat Rev. 1994;62(2):229–43.
19. Centers for Disease Control and Prevention. HIV risk, prevention, and testing behaviors – national HIV behavioral surveillance system: men who have sex with men, 20 U.S. Cities. 2011. HIV Surveillance Special Report 8. 2014.
20. MacKellar DA, Gallagher JL, Finkin J, Sanchez T, Lansky A, Sullivan PS. Surveillance of HIV risk and prevention behaviors of men who have sex with men – a national application of venue-based, time-space sampling. Public Health Rep. 2007;122 Suppl 1:39–47.
21. Moore RD. Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort. J Acquire Immune Defic Syndr Hum Retrovirology. 1996;17 Suppl 1:S38–41.
22. Maulsbury C, Sifakis F, Germain D, Flynn OP, Holtgrave D. Partner characteristics and undiagnosed HIV seropositivity among men who have sex with men only (MSMO) and men who have sex with men and women (MSMW) in Baltimore, AIDS Behav. 2012;16(3):543–53.
23. Hall HI, Frazier EL, Rhodes P, Holtgrave DR, Furlow-Parmley C, Tang T, et al. Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med. 2013;173(14):1337–44.
24. Singh S, Bradley H, Hu X, Skarbinski J, Hall HI, Lansky A. Men living with diagnosed HIV who have sex with men: progress along the continuum of HIV care – United States, 2010. MMWR Morb Mortal Wkly Rep. 2014;63(38):829–33.
25. German D, Shearer K, Park JN, Flynn C, Latkin C, Laeyendecker O, et al. Factors associated with misreporting HIV status among MSMO and MSMW in Baltimore City. AIDS Behav. 2012;16(3):543–53.
27. Emory University, Rollins School of Public Health. AIDS Vu 2018 [cited 2018 Sep 20]. Available from aidsvu.org.
28. Kelly SL, Wilson DP. HIV cascade monitoring and simple modeling reveal potential for reductions in HIV incidence. J Acquir Immune Defic Syndr. 2015a;69(3):257–63.
29. Medlock J, Pandey A, Parpia AS, Tang A, Skrip LA, Galvan AP. Effectiveness of UNAIDS targets and HIV vaccination across 127 countries. Proc Natl Acad Sci U S A. 2017;114(15):4017–22.
30. Shah M, Perry A, Risher K, Kapoor S, Grey J, Sharma A, et al. Effect of the US National HIV/AIDS Strategy targets for improved HIV care engagement: a modelling study. Lancet HIV. 2016;3(3):e140–6.
31. Bonacci RA, Holtgrave DR. U.S. HIV incidence and transmission goals, 2020: modelling study. Lancet HIV. 2016;3(3):e140–6.
32. San Francisco Department of Public Health. HIV epidemiology annual report 2015. San Francisco: San Francisco Department of Public Health; 2016.
33. Wilson C. Massive drop in London HIV rates may be due to internet drugs. New Sci. 2017.
34. German D, Brady K, Kuo I, Opoku J, Flynn C, Patrick R, et al. Characteristics of Black men who have sex with men in the United States, Philadelphia, and Washington, D.C.: Geographic Diversity in Socio-Demographics and HIV Transmission Risk. J Acquir Immune Defic Syndr. 2017;75 Suppl 3:S296–308.
35. Hoots BE, Finlayson TJ, Weinert C, Paz-Bailly G. Early linkage to HIV care and antiretroviral treatment among men who have sex with men – 20 cities, United States, 2008 and 2011. PLoS ONE. 2015;10(7):e0132962.
36. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumaranayake L, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375:830–9.
37. Novak RM, Hart RE, Chmiel JS, Brooks JT, Buchacz K. Disparities in initiation of combination antiretroviral treatment and in virologic suppression among patients in the HIV Outpatient Study (HOPS), 2000-2013. J Acquir Immune Defic Syndr. 2015;70(1):23–29.
38. Weintrob AC, Grandits GA, Agan BK, Ganesan A, Landrum ML, Crum-Cianflone NF, et al. Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr. 2009;52(5):574–80.
39. Althoff KN, Rebeiro P, Brooks JT, Buchacz K, Gebo K, Martin J, et al. Disparities in the quality of HIV care when using US Department of Health and Human Services indicators. Clin Infect Dis. 2014;58(8):1185–9.
40. Li X, Margolick JB, Conover CS, Badri S, Riddler SA, Witt MD, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2005;38(3):320–8.
41. Tedaldi EM, Richardson JT, Debes R, Young B, Chmiel JS, Durham MD, et al. Retention in care within 1 year of initial HIV care visit in a multisite US cohort: who’s in and who’s out? J Int Assoc Provid AIDS Care. 2014;13(3):232–41.
42. Rebeiro P, Althoff KN, Buchacz K, Gill J, Horberg M, Krentz H, et al. Retention among North American HIV-infected persons in clinical care. 2000-2008. J Acquir Immune Defic Syndr. 2013;62(3):356–62.
43. Howe CJ, Cole SR, Napravnik S, Eron JJ. Enrollment, retention, and visit attendance in the University of North Carolina Center for AIDS Research HIV clinical cohort, 2001-2007. AIDS Res Hum Retroviruses. 2010;26(8):875–81.
44. Krishnan S, Wu K, Smurzynski M, Bosch RJ, Benson CA, Collier AC, et al. Incidence rate of and factors associated with loss to follow-up in a longitudinal cohort of antiretroviral-treated HIV-infected persons: an AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) analysis. HIV Clin Trials. 2011;12(4):190–200.
45. Dasgupta S, Oster AM, Li J, Hall HI. Disparities in consistent retention in HIV care – 11 states and the district of Columbia, 2011-2013. MMWR Morb Mortal Wkly Rep. 2016;65(4):77–82.
46. Moore RD, Keruly JC, Bartlett JC. Improvement in the health of HIV-infected persons in care: reducing disparities. Clin Infect Dis. 2012;55(9):1242–51.
47. Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2015;68(3):337–44.

SUPPORTING INFORMATION

Additional Supporting Information may be found in the online version of this article:

Figure S1: Age groups, race groups, movement and mixing in the model.
Figure S2: HIV disease progression, by HIV states and set-point viral load, for those not on antiretroviral therapy (ART), and for those on ART but not adherent.
Figure S3: Different stages of HIV care and transitions between them.
Figure S4: Illustration of calculations of targets and outcomes.
Figure S5: Outcomes for model fits.
Figure S6: Required increase in viral suppression in 2020 above initial 2015 level needed to meet a 50% incidence reduction compared with the base-case scenario in 2020, for all runs across all fits, against initial level of viral suppression in 2015.
Figure S7: Correlations between the increase in care continuum parameters above 2015 levels (y-axis) and the relative reduction in HIV incidence after five years, for all runs.
Figure S8: New HIV diagnoses over time under the base-case scenario and when different US targets are met in 2020.
Figure S9: HIV incidence (new cases per 100 uninfected men per year) over time under the base-case scenario and when different targets are met.
Table S1: Parameters used in the HIV transmission model, with source and justification.
Table S2: Data fitted to, with fitting bounds, source and justification.
Table S3: Probability of reaching HIV elimination within 20 years when meeting different (a) trial incidence reduction targets after different time periods; (b) US continuum targets in 2020; (c) UNAIDS targets in 2020.
Appendix S1: Methods.